We are very proud at LEO Pharma that, as well as our firmly established therapy areas of Dermatology (skin) and Thrombosis (blood clots), we established a BioDermatology division in 2016 following the announcement of an exciting strategic partnership with Astra Zeneca. This marked the entry by LEO Pharma into developing innovative biologic therapies for skin conditions, firstly psoriasis and atopic dermatitis. 

Building on our long-established heritage and expertise in topical treatments (those applied to the skin), starting from 2017, LEO Pharma is in the exciting position of providing products and resources for people living with psoriasis across the entire disease severity spectrum, in both primary and secondary care. This represents a key step in our growth journey.

Our BioDermatology division provides great opportunities for personal development for our current team to build on their skills and knowledge-base, as well as offering new roles for people who may want to join us on this exciting journey. 

To learn more about opportunities in the team visit our Vacancies page

To learn more about our products visit Our Products page

Cookies on this site

LEO Laboratories Limited uses cookies to give you the best experience online and to provide anonymised, aggregated site usage data. You can find out what cookies we use, what they do and how you can disable them in our Cookie Policy. By browsing our sites, you consent to the use of cookies. If you want to know more about our cookie policy and how to avoid and delete cookies click here. By continuing to browse this site, you consent to our use of cookies on this device in accordance with our cookie policy unless you have disabled them.